keyword
MENU ▼
Read by QxMD icon Read
search

iodine therapy

keyword
https://www.readbyqxmd.com/read/28335429/the-adverse-effect-of-hypertension-in-the-treatment-of-thyroid-cancer-with-multi-kinase-inhibitors
#1
REVIEW
Ole Vincent Ancker, Markus Wehland, Johann Bauer, Manfred Infanger, Daniela Grimm
The treatment of thyroid cancer has promising prospects, mostly through the use of surgical or radioactive iodine therapy. However, some thyroid cancers, such as progressive radioactive iodine-refractory differentiated thyroid carcinoma, are not remediable with conventional types of treatment. In these cases, a treatment regimen with multi-kinase inhibitors is advisable. Unfortunately, clinical trials have shown a large number of patients, treated with multi-kinase inhibitors, being adversely affected by hypertension...
March 14, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28325735/rescue-preoperative-treatment-with-lugol-s-solution-in-uncontrolled-graves-disease
#2
Jan Calissendorff, Henrik Falhammar
BACKGROUND: Graves' disease is a common cause of hyperthyroidism. Three therapies have been used for decades: pharmacologic therapy, surgery and radioiodine. In case of adverse events, especially agranulocytosis or hepatotoxicity, pre-treatment with Lugol's solution containing iodine/potassium-iodide to induce euthyroidism before surgery could be advocated but has rarely been reported. METHOD: All patients hospitalised due to uncontrolled hyperthyroidism at the Karolinska University Hospital 2005-2015 and treated with Lugol's solution were included...
March 21, 2017: Endocrine Connections
https://www.readbyqxmd.com/read/28325623/impact-of-body-mass-index-on-survival-outcome-in-patients-with-differentiated-thyroid-cancer
#3
Yousif Al-Ammar, Bader Al-Mansour, Omar Al-Rashood, Mutahir A Tunio, Tahera Islam, Mushabbab Al-Asiri, Khalid Hussain Al-Qahtani
INTRODUCTION: Increased body mass index (BMI) is known to be associated with the high prevalence of Differentiated Thyroid Cancers (DTC); however data on its impact on survival outcome after thyroidectomy and adjuvant therapy is scanty. OBJECTIVE: We aimed to evaluate the impact of BMI on overall survival (OS) and disease free survival (DFS) rates in patients with DTC. METHODS: Between 2000 and 2011, 209 patients with DTC (papillary, follicular, hurthle cell) were treated with thyroidectomy followed by adjuvant radioactive iodine-131 (RAI) therapy and thyroid-stimulating hormone (TSH) suppression...
February 28, 2017: Brazilian Journal of Otorhinolaryngology
https://www.readbyqxmd.com/read/28318881/targeted-therapy-in-thyroid-cancer-state-of-the-art
#4
L Valerio, L Pieruzzi, C Giani, L Agate, V Bottici, L Lorusso, V Cappagli, L Puleo, A Matrone, D Viola, C Romei, R Ciampi, E Molinaro, R Elisei
Thyroid cancer typically has a good outcome following standard treatments, which include surgery, radioactive iodine ablation for differentiated tumours and treatment with thyrotropine hormone-suppressive levothyroxine. Thyroid cancers that persist or recur following these therapies have a poorer prognosis. Cytotoxic chemotherapy or external beam radiotherapy has a low efficacy in these patients. 'Target therapy' with tyrosine kinase inhibitors (TKIs) represent an important therapeutic option for the treatment of advanced cases of radioiodine refractory (RAI-R) differentiated thyroid cancer (DTC), medullary thyroid cancer (MTC) and possibly for cases of poorly differentiated (PDTC) and anaplastic thyroid cancer (ATC)...
March 16, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28315902/postoperative-radioactive-iodine-131-ablation-is-not-necessary-among-patients-with-intermediate-risk-differentiated-thyroid-carcinoma-a-population-based-study
#5
Hong Zhang, Yuechang Cai, Li Zheng, Zhanlei Zhang, Ningyi Jiang
OBJECTIVE: To assess the effectiveness of radioactive iodine (RAI) ablation among patients with intermediate-risk differentiated thyroid cancer (DTC) following surgery. SUBJECTS AND METHODS: This population based study obtained information from the Surveillance, Epidemiology, and End Results (SEER) Program Research Data (1973-2013). National Cancer Institute, DCCPS, Surveillance Research Programme, Surveillance Systems Branch, released April 2016, based on the November 2015 submission...
March 20, 2017: Hellenic Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/28306621/prognostic-value-of-preoperative-18f-fdg-pet-ct-in-papillary-thyroid-cancer-patients-with-a-high-metastatic-lymph-node-ratio-a-multicenter-retrospective-cohort-study
#6
Seong Young Kwon, Eun Kyoung Choi, Eun Jung Kong, Ari Chong, Jung-Min Ha, Kyung Ah Chun, Ihn Ho Cho, Hee-Seung Bom, Jung-Joon Min, Jahae Kim, Ho-Chun Song, Joo Hyun O, Sung Hoon Kim
OBJECTIVE: Metastatic lymph node ratio (MLNR) is a known significant predictor of disease-free survival in differentiated thyroid cancer. The authors investigated the ability of preoperative fluorine-18 fluorodeoxyglucose (F-FDG) PET/CT to predict recurrence after surgery with radioactive iodine therapy considering MLNR. PATIENTS AND METHODS: A total of 274 patients who underwent preoperative PET/CT and surgery with radioactive iodine therapy were enrolled. The tumor-to-liver uptake ratio on PET/CT was calculated by dividing the maximum standardized uptake value of a primary lesion by the mean standardized uptake value of the normal liver...
March 16, 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28301826/a-multicenter-phase-ii-study-of-sunitinib-in-patients-with-locally-advanced-or-metastatic-differentiated-anaplastic-or-medullary-thyroid-carcinomas-mature-data-from-the-thysu-study
#7
Alain Ravaud, Christelle de la Fouchardière, Philippe Caron, Adelaïde Doussau, Christine Do Cao, Julien Asselineau, Patrice Rodien, Damien Pouessel, Patricia Nicolli-Sire, Marc Klein, Claire Bournaud-Salinas, Jean-Louis Wemeau, Anne Gimbert, Marie-Quitterie Picat, Delphine Pedenon, Laurence Digue, Amaury Daste, Bogdan Catargi, Jean-Pierre Delord
PURPOSE: Patients with advanced radioactive iodine resistant differentiated (MDTC) or medullary (MMTC) thyroid cancer had an unmet need. Early data showed promising efficacy of vascular endothelial growth factor receptor inhibitors. We investigated sunitinib in this setting. PATIENTS AND METHODS: This phase 2 trial enrolled MDTC, anaplastic (MATC) and MMTC patients in 1st line anti-angiogenic therapy with sunitinib at 50 mg/d, 4/6w. Objective response rate was the primary end-point...
March 13, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28295509/measuring-tsh-receptor-antibody-trab-to-influence-treatment-choices-in-graves-disease
#8
Asha Hesarghatta Shyamasunder, Prakash Abraham
TSH receptor antibody (TRAb) plays a key role in the pathogenesis of Graves' disease (GD) and its levels correlate with the clinical course. The 2(nd) and 3(rd) generation TRAb assays have >95% sensitivity and specificity for the diagnosis of GD, and have improved the utility of TRAb to predict relapse. TRAb levels decline with antithyroid drug (ATD) therapy and after thyroidectomy. Its level increases for a year following radioactive iodine (RAI) therapy, with a gradual fall thereafter. TRAb level >12 IU/L at diagnosis of GD is associated with 60% risk of relapse at 2 years and 84% at 4 years...
March 13, 2017: Clinical Endocrinology
https://www.readbyqxmd.com/read/28294040/racial-disparities-in-differentiated-thyroid-cancer-have-we-bridged-the-gap
#9
Syed A Shah, Mohamed Abdelgadir Adam, Samantha Thomas, Randall P Scheri, Michael Stang, Julie Ann Sosa, Sanziana Roman
BACKGROUND: Racial disparities in the management of differentiated thyroid cancer (DTC) exist in the U.S.; there is a paucity of data examining their temporal trends. We hypothesized that racial disparities in care provided to patients with differentiated thyroid cancer have improved over the past 15 years. METHODS: Adult patients undergoing surgery for DTC were included from the National Cancer Data Base (1998-2012). Temporal trends in appropriate extent of thyroidectomy and radioactive iodine therapy (RAI) were described for different racial groups...
March 15, 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/28292215/the-role-of-postoperative-stimulated-thyroglobulin-as-prognostic-factor-for-differentiated-thyroid-cancer-in-children-and-adolescents
#10
André B Zanella, Rafael Selbach Scheffel, Marina Pasa, Jose Miguel Dora, Ana Luiza Maia
BACKGROUND: Prognostic factors are essential for risk stratification in patients with differentiated thyroid carcinoma (DTC). The role of stimulated postoperative thyroglobulin (sPOTg) has been well-established in adult DTC population but it remains unclear in children and adolescents. Here, we aimed to evaluate potential prognostic factors in children and adolescents with DTC, with special emphasis on sPOTg analysis. METHODS: Individuals aged 18 years or younger at diagnosis were selected from a cohort of DTC patients attending the thyroid clinic of a tertiary university-based hospital...
March 14, 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/28291505/the-high-prevalence-of-reversible-subclinical-hypothyroidism-with-elevated-serum-thyroglobulin-levels-in-chronic-kidney-disease-patients%C3%A2
#11
Toru Sanai, Ken Okamura, Shuichi Rikitake, Makoto Fukuda, Koji Onozawa, Mai Sanematsu, Tsuyoshi Takashima, Motoaki Miyazono, Yuji Ikeda
BACKGROUND: We examined the thyroid function of non-dialysis-dependent chronic kidney disease (CKD) patients in Japan. METHODS: Serum-free thyroxine, free triiodothyronine, thyroid-stimulating hormone (TSH), and thyroglobulin (Tg) levels were evaluated in 37 CKD patients. CKD was defined as sustained kidney damage for more than 3 months and was classified as CKD 1+2 (n = 11), 3+4 (n = 10), or 5 (n = 16), which were defined by glomerular filtration rates of ≥ 60, 15 - 59, or < 15 mL/min/1...
March 14, 2017: Clinical Nephrology
https://www.readbyqxmd.com/read/28291381/selimetry-a-multicentre-i-131-dosimetry-trial-a-clinical-perspective
#12
Jonathan Wadsley, Rebecca Gregory, Glenn Flux, Kate Newbold, Yong Du, Laura Moss, Andrew Hall, Louise Flanagan, Sarah R Brown
Treatment options for patients with thyroid cancer that is no longer sensitive to iodine therapy are limited. Those treatments which currently exist are associated with significant toxicity. The SELIMETRY trial (EudraCT No 2015-002269-47) aims to investigate the role of the MEK inhibitor Selumetinib in re-sensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy. Patients deemed to have sufficient iodine uptake in previously iodine refractory lesions after 4 weeks of Selumetinib therapy will be given an empirical activity of 5...
March 14, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28291010/ectopic-pelvic-kidney-mimicking-sacral-metastasis-on-post-therapy-iodine-131-scan-of-a-thyroid-cancer-patient
#13
Selin Soyluoğlu Demir, Gül Ege Aktaş, Ahmet Polat, Ali Sarıkaya
A 25-year-old woman had total thyroidectomy and iodine-131 ablation therapy for papillary thyroid carcinoma. Whole body imaging on the 7(th) day of therapeutic activity demonstrated radioiodine uptake in the remnant tissue and intense heterogeneous uptake at the sacral region prominently in the posterior image. Initial interpretation was suspicious for sacral metastasis. Technetium-99m-methylene diphosphonate bone scan demonstrated normal bone uptake and the absence of left kidney. On blood-pool phase of bone scan, the absence of left renal activity and an extra area of uptake in the sacral region suggestive of pelvic kidney were noticed...
February 5, 2017: Molecular Imaging and Radionuclide Therapy
https://www.readbyqxmd.com/read/28291004/-18-f-fluorodeoxyglucose-positron-emission-tomography-computed-tomography-for-other-thyroid-cancers-medullary-anaplastic-lymphoma-and-so-forth
#14
Mine Araz, Derya Çayır
Positron emission tomography/computed tomography (PET/CT) with (18)F-fluorodeoxyglucose (FDG) is used in staging, restaging, and evaluation of therapy response in many cancers as well as differentiated thyroid carcinomas especially in non-iodine avid variants. Its potential in less frequent thyroid tumors like medullary, anaplastic thyroid cancers, thyroid lymphoma and metastatic tumors of the thyroid however, is not well established yet. The aim of this review is to provide an overview on the recent applications and indications of (18)F-FDG PET/CT in these tumors and to focus on the controversies in the clinical setting...
February 5, 2017: Molecular Imaging and Radionuclide Therapy
https://www.readbyqxmd.com/read/28290642/radioactive-iodine-therapy-vs-antithyroid-medications-for-graves-disease
#15
Julie Petersen, Kenneth W Lin
No abstract text is available yet for this article.
March 1, 2017: American Family Physician
https://www.readbyqxmd.com/read/28283939/high-dose-of-radioactive-iodine-per-se-has-no-effect-on-glucose-metabolism-in-thyroidectomized-rats
#16
Roghaieh Samadi, Mahboubeh Ghanbari, Babak Shafiei, Sevda Gheibi, Fereidoun Azizi, Asghar Ghasemi
PURPOSE: Thyroid concentrates radioactive iodine by sodium-iodide symporter; this is used for treating hyperthyroidism and thyroid cancer. Pancreas expresses NIS and radioactive iodine uptake may damage pancreatic beta-cells and predispose patients to type 2 diabetes. The aim of this study was to determine whether radioactive iodine is associated with glucose metabolism in thyroidectomized rats. METHODS: Forty male Wistar rats were divided into four groups (n = 10/each); control, thyroidectomized, thyroidectomized-treated with 131-I (TX+I), and thyroidectomized-treated with 131-I and L-thyroxine (TX+I+T4)...
March 10, 2017: Endocrine
https://www.readbyqxmd.com/read/28279069/brain-and-organ-uptake-in-the-rhesus-monkey-in-vivo-of-recombinant-iduronidase-compared-to-an-insulin-receptor-antibody-iduronidase-fusion-protein
#17
Ruben J Boado, William M Pardridge
Mucopolysaccharidosis type I (MPSI) is caused by mutations in the gene encoding the lysosomal enzyme, α-l-iduronidase (IDUA), and patients with MPSI are currently treated with IDUA enzyme replacement therapy (ERT). However, the majority of MPSI patients have severe CNS involvement, and conventional ERT does not treat the brain. The failure of ERT to treat the brain is believed to be due to the lack of IDUA transport through the blood-brain barrier (BBB). However, BBB transport of IDUA has not been directly measured, to date...
March 16, 2017: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/28274949/management-of-endocrine-disease-subclinical-thyrotoxicosis-prevalence-causes-and-choice-of-therapy
#18
Allan Carle, Stine Linding Andersen, Kristien Boelaert, Peter Laurberg
Subclinical thyrotoxicosis is a condition affecting up to 10% of the population in some studies. We have reviewed literature and identified studies describing prevalences, causes and outcomes of this condition. Treatment should be considered in all subjects if this biochemical abnormality is persistent, especially in case of symptoms of thyrotoxicosis or in the presence of any complication. In particular, treatment should be offered in those subclinically thyrotoxic patients with a sustained serum TSH below 0...
March 8, 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/28271395/comparing-pre-therapeutic-124-i-and-131-i-uptake-tests-with-intra-therapeutic-131-i-uptake-in-benign-thyroid-disorders
#19
Falk Gühne, Christian Kühnel, Martin Freesmeyer
PURPOSE: (124)I-PET/CT can be used for pre-therapeutic assessment of radioactive iodine uptake in benign thyroid disorders, however systematic comparisons with intra-therapeutic uptake are still lacking for these disorders. The goals of this study were to compare (124)I RAIU and conventional (131)I RAIU tests with each other; to compare both tests with intra-therapeutic uptake (reference); and to verify the time course of radioactive iodine uptake at three time points (30, 102, and 336 h [14 days] post administration; p...
March 7, 2017: Endocrine
https://www.readbyqxmd.com/read/28270435/timing-of-multikinase-inhibitor-initiation-in-differentiated-thyroid-cancer
#20
Marcia S Brose, Jan Wa Smit, Chia-Chi Lin, Fabian Pitoia, Marc Fellous, Yoriko DeSanctis, Martin Schlumberger, Masayuki Tori, Iwao Sugitani
There are limited treatment options for patients with radioactive iodine-refractory, progressive differentiated thyroid cancer. Although there is consensus that multikinase inhibitor therapy should be considered in patients with progressive disease with considerable tumor load or symptomatic disease, uncertainty exists on the optimal timing to treat with a multikinase inhibitor, especially for asymptomatic patients. RIFTOS MKI is an international, prospective, open-label, multicenter, noninterventional study with the primary objective to compare the time to symptomatic progression from study entry in asymptomatic patients with radioactive iodine -refractory, progressive differentiated thyroid cancer for whom there is a decision to initiate multikinase inhibitors at study entry (cohort 1) with those for whom there is a decision to not initiate multikinase inhibitors at study entry (cohort 2)...
March 7, 2017: Endocrine-related Cancer
keyword
keyword
103407
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"